A Phase 2 interventional study of Necitumumab and Nab-Paclitaxel in Carcinoma, Non-Small Cell Lung Cancer (NSCLC), sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-19.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.
Among the 402 studies in Carcinoma with a site in United States, this one is the 155th largest by enrollment of the 358 interventional ones that give a count, is one of 13 that started in 2015, is one of 117 in phase 2, and was the 197th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Pfizer · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
402 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 171 · Phase 3 53 · Phase 4 7
First in 1996; this study’s year is marked. 13 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 48 across the 358 interventional studies, 108 across the 40 observational. Of the 267 that completed or were terminated, 121 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 402 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 9 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Carcinoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05050162Phase 3NRG OncologyComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | 2027-02-09 |
| NCT06693336ToLymph Inc.An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | 2026-11-18 |
| NCT04520711Providence Health & ServicesHotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 2026-12 |
| NCT05768932SillaJen, Inc.BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | 2026-12-24 |
Add all 35 to your calendar (.ics) → With an account.
Among the 402 studies in Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg\*min/mL) on day 1 of each cycle, for a maximum of 4 cycles. Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles). Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Necitumumab · Drug: Nab-Paclitaxel · Drug: Carboplatin
Administered IV
Also known as: LY3012211, IMC-11F8
Administered IV
Also known as: Abraxane
Administered IV
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: From Date of Randomization to Objective Disease Progression (Up to 18 Months)
Progression Free Survival (PFS)
PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.
Time frame: From Date of Randomization to Measured Progressive Disease or Death Due to Any Cause (Up to 18 Months)
Overall Survival (OS)
OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.
Time frame: From Date of Randomization until Death Due to Any Cause (Up to 18 Months)
Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: From Date of Randomization to Objective Disease Progression or Start of New Anticancer Therapy (Up to 18 Months)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin
The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.
Time frame: Cycle 3 and cycle 4: predose
PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin
The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.
Time frame: Cycle 1, 3 and 4: predose and <15minutes (min) post end-of-infusion
Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab
A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.
Time frame: Predose Cycle 1 Through Short Term Follow Up (Up To 18 Months)
| Milestone | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Started | 54 |
| Received at least 1 dose of study drug | 54 |
| Completed | 47 |
| Not completed | 7 |
| Withdrew: Death | 3 |
| Withdrew: On study treatment at study conclusion | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Milestone | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Started | 34 |
| Completed | 32 |
| Not completed | 2 |
| Withdrew: Death | 1 |
| Withdrew: On study treatment at study conclusion | 1 |
ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) | 51.0 |
PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.
| Months | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Progression Free Survival (PFS) | 5.59 (4.24 to 7.69) |
OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.
| Months | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Overall Survival (OS) | 15.54 (10.18 to NA) |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) | 78.4 |
The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.
| nanogram per milliliter (ng/mL) | Necitumumab | Carboplatin | Paclitaxel |
|---|---|---|---|
| Cycle 3 | 65.2 ± 86.9 | 0.131 ± 36 | 33.6 ± 393 |
| Cycle 4 | 90 ± 74.9 | 0.209 ± 197 | 107 ± 313 |
The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.
| ng/mL | Necitumumab | Carboplatin | Paclitaxel |
|---|---|---|---|
| Cycle 1 | 231 ± 27.1 | 16.4 ± 22 | 343 ± 81.2 |
| Cycle 3 | 291 ± 46.5 | 16 ± 26.4 | 284 ± 73 |
| Cycle 4 | 277 ± 42.5 | 10.5 ± 160 | 221 ± 77.6 |
A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.
| Participants | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab | 3 |
Collected over Baseline Up to 49 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Necitumumab + Nab-paclitaxel + Carboplatin: Induction Phase | 3/54 (5.6%) | 18/54 (33.3%) | 54/54 (100%) |
| Necitumumab + Nab-paclitaxel: Maintenance Phase | 1/34 (2.9%) | 5/34 (14.7%) | 31/34 (91.2%) |
| Event | Necitumumab + Nab-paclitaxel + Carboplatin: Induction Phase | Necitumumab + Nab-paclitaxel: Maintenance Phase |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/54 | 0/34 |
| NauseaGastrointestinal disorders | 2/54 | 0/34 |
| FatigueGeneral disorders | 2/54 | 1/34 |
| Respiratory tract infectionInfections and infestations | 2/54 | 0/34 |
| Neutrophil count decreasedInvestigations | 2/54 | 0/34 |
| Myocardial infarctionCardiac disorders | 0/54 | 1/34 |
| DeathGeneral disorders | 0/54 | 1/34 |
| PneumoniaInfections and infestations | 0/54 | 1/34 |
| FallInjury, poisoning and procedural complications | 1/54 | 1/34 |
| Femur fractureInjury, poisoning and procedural complications | 1/54 | 1/34 |
| Event | Necitumumab + Nab-paclitaxel + Carboplatin: Induction Phase | Necitumumab + Nab-paclitaxel: Maintenance Phase |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 34/54 | 15/34 |
| FatigueGeneral disorders | 32/54 | 6/34 |
| Neutrophil count decreasedInvestigations | 32/54 | 1/34 |
| HypomagnesaemiaMetabolism and nutrition disorders | 26/54 | 7/34 |
| RashSkin and subcutaneous tissue disorders | 20/54 | 6/34 |
| DiarrhoeaGastrointestinal disorders | 19/54 | 4/34 |
| ConstipationGastrointestinal disorders | 18/54 | 2/34 |
| Platelet count decreasedInvestigations | 17/54 | 2/34 |
| NauseaGastrointestinal disorders | 16/54 | 2/34 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 16/54 | 4/34 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Mean | 65.96 ± 7.48 |
| Sex: Female, Male(Participants) | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Female | 12 |
| Male | 42 |
| Ethnicity (NIH/OMB)(Participants) | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 50 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 53 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Necitumumab + Nab-Paclitaxel + Carboplatin |
|---|---|
| United States | 15 |
| Germany | 4 |
| Spain | 27 |
| Greece | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2015 to primary completion in Jan 2018, 27 months.
Results were first posted in Feb 2019, 1 year after primary completion.
Of 83 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Necitumumab · Albumin-Bound Paclitaxel · Carboplatin